Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG (BAYN)

Delayed Quote. Delayed  - 08/24 05:35:23 pm
96.72 EUR   +0.05%
08/23DJU.S. Lawmakers Plan Hearing Over Wave of Agriculture Mergers
08/22 BAYER : Not intended for U.S. and UK Media -- New Real-World Evidenc..
08/17 BAYER : and the Canadian Vascular Network (CVN) Announce the 2016 Re..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Bayer AG : Expansion of germplasm-pool for wheat:

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/14/2011 | 11:30am CEST
Bayer CropScience acquires access to wheat germplasm from leading Romanian agricultural research institution
Monheim, October 14, 2011 – Bayer CropScience and the National Agricultural Research and Development Institute (NARDI) in Fundulea/Romania have signed a license agreement. With this agreement, Bayer gains access to winter wheat germplasm of NARDI, the leading Romanian agricultural research institution. Its germplasm pool is renowned world-wide for its winter hardiness, high tolerance against drought, broad disease resistance and good milling and baking quality. Financial details were not disclosed.
“Improving the productivity of wheat cropping will be critical to achieving global food security. Our customers have turned to us to find new ways to help them, we have listened and are building a world-class research platform for wheat genetics. Our agreement with NARDI is another key building block in this strategy“, said Hartmut van Lengerich, Head of Cereals and Fungicides at Bayer CropScience. “To speed up development of new varieties, we have already entered into collaborations with the best partners in wheat research and breeding, reaching from Australia to Israel, France and Ukraine to the United States – and now Romania.”
“Producing enough wheat to feed the world is an immense challenge and anyone willing to invest in the effort to meet this challenge is welcome”, said Marian Verzea, General Director of NARDI. “NARDI is proud that the wheat germplasm developed by its breeding program will be used to speed up genetic progress in breeding better wheat cultivars for other parts of the world, too.”
Key figures about wheat:
With about 25 percent of the global agricultural land under wheat cultivation, it is the largest cereal crop in terms of acreage and one of the world’s most important staple foods. Wheat is the second most-produced cereal crop after corn with more than 650 million tons produced every year. Wheat productivity is increasing at less than 1 percent annually, while the annual global demand is growing at approximately double that percentage. Main wheat producing regions are Australia, the Black Sea Region, China, the EU, India and North America.
About Bayer CropScience
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer CropScience, a subgroup of Bayer AG with annual sales of EUR 6.830 billion (2010), is one of the world’s leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and traits. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of 20,700 and is represented in more than 120 countries. This and further news is available at: www.press.bayercropscience.com.
About NARDI
NARDI Fundulea is recognized as the main agricultural research unit in Romania, due to the results obtained in breeding and crop management research & development regarding cereals, industrial and forage crops. Results of wheat breeding have a special place in NARDI’s research portfolio. NARDI’s twenty nine common wheat cultivars released since 1957 have had the largest share of the Romanian wheat seed market for more than 30 years, while nine NARDI wheat cultivars have been released in other countries, such as Canada, Argentina, Hungary, Turkey. Further information is available at: www.incda-fundulea.ro
Find more information at www.bayercropscience.com.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
08/23DJU.S. Lawmakers Plan Hearing Over Wave of Agriculture Mergers
08/22 COVESTRO : Assigned Patent
08/22 BAYER : Not intended for U.S. and UK Media -- New Real-World Evidence on Venous ..
08/18 BAYER CROPSCIENCE : Research Conducted at Bayer CropScience Has Provided New Inf..
08/17 BAYER : and the Canadian Vascular Network (CVN) Announce the 2016 Research Fello..
08/15 Covestro LLC Receives US2020's 2016 STEM Mentoring Award for 'Excellence in C..
08/12 COVESTRO : Longer lives, greater financial needs lead to delayed retirements
08/11DJEU Opens Antitrust Probe on Dow Chemical-DuPont Merger
08/11 Covestro LLC Receives US2020's 2016 STEM Mentoring Award for 'Excellence in C..
08/05 BAYER : reported to be reviewing Monsanto's books as it mulls higher bid
More news
Sector news : Pharmaceuticals - NEC
08/24DJPFIZER : Buys Part of AstraZeneca's Antibiotics Business -- 2nd Update
08/24DJASTRAZENECA : Sells Part of its Antibiotics Business to Pfizer -- Update
08/24DJPfizer Buys Part of AstraZeneca's Antibiotics Business
08/24DJASTRAZENECA : Sells Part of Antibiotics Business to Pfizer for Up to $1.575 Bill..
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/23 Who's Next After Medivation?
08/23 Apple Wants You To Feel Better
08/23 BLOOMBERG : Bayer, Monsanto moving closer to deal
08/22 Berkshire Boosts Apple Stake And Other Moves From Top Managers
08/19 Bayer/CRISPR Therapeutics joint venture Casebia Therapeutics establishes oper..
Advertisement
Financials (€)
Sales 2016 46 964 M
EBIT 2016 8 224 M
Net income 2016 4 747 M
Debt 2016 15 954 M
Yield 2016 2,77%
P/E ratio 2016 17,61
P/E ratio 2017 14,95
EV / Sales 2016 2,04x
EV / Sales 2017 1,89x
Capitalization 79 941 M
More Financials
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 109 €
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Human Resources, Technology & Sustainability
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-16.48%90 245
JOHNSON & JOHNSON15.57%326 773
ROCHE HOLDING LTD.-11.47%219 257
NOVARTIS AG-9.45%214 603
PFIZER INC.7.87%212 844
MERCK & CO., INC.18.76%175 812
More Results